NCT03368053View on ClinicalTrials.gov

Long-term Immunogenicity of the HIV gp120-NefTat/AS01B Vaccine (GSK SB732461)

PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

December 14, 2017

Primary Completion Date

January 30, 2018

Study Completion Date

January 30, 2018

Conditions
Infection, Human Immunodeficiency VirusHIV Infections
Interventions
PROCEDURE

Blood sampling

Blood samples will be taken during the single study visit at Year 14 for the assessment of: HIV testing, antibody determination, cell mediated immune (CMI) responses and exploratory characterisation.

Trial Locations (1)

9000

GSK Investigational Site, Ghent

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
collaborator

University Ghent

OTHER

lead

GlaxoSmithKline

INDUSTRY